Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 2
2015 2
2016 5
2017 4
2018 2
2019 5
2020 7
2021 2
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals.
Marjani M, Tabarsi P, Moniri A, Hashemian SM, Nadji SA, Abtahian Z, Malekmohammad M, Kiani A, Farzanegan B, Eslaminejad A, Fakharian A, Heshmatnia J, Abedini A, Seifi S, Yassari F, Mirenayat MS, Rezaei M, Sheikhzade H, Ahmadi ZH, Dastan F, Sadeghi M, Lookzadeh S, Porabdollah M, Askari E, Baghaei P, Mansourafshar B, Jahangirifard A, Vasheghani M, Mokhber Dezfuli M, Varahram M, Jamaati H, Mansouri D, Zali A, Velayati AA. Marjani M, et al. Among authors: eslaminejad a. Tanaffos. 2020 Nov;19(2):91-99. Tanaffos. 2020. PMID: 33262795 Free PMC article. Review. No abstract available.
Transmission electron microscopy study of suspected primary ciliary dyskinesia patients.
Rezaei M, Soheili A, Ziai SA, Fakharian A, Toreyhi H, Pourabdollah M, Ghorbani J, Karimi-Galougahi M, Mahdaviani SA, Hasanzad M, Eslaminejad A, Ghaffaripour HA, Mahmoudian S, Rodafshani Z, Mirenayat MS, Varahram M, Marjani M, Tabarsi P, Mansouri D, Jamaati HR, Velayati AA. Rezaei M, et al. Among authors: eslaminejad a. Sci Rep. 2022 Feb 11;12(1):2375. doi: 10.1038/s41598-022-06370-w. Sci Rep. 2022. PMID: 35149751 Free PMC article.
Pulmonary manifestations in a cohort of patients with inborn errors of immunity: an 8-year follow-up study.
Movahedi M, Jamee M, Ghaffaripour H, Noori F, Ghaini M, Eskandarzadeh S, Enayat J, Eslamian G, Pourdowlat G, Sharifinejad N, Poorabdollah M, Nadji SA, Fallahi M, Daneshmandi Z, Heshmatnia J, Eslaminejad A, Fakharian A, Vasheghani M, Moniri A, Mirenayat MS, Tabarsi P, Marjani M, Rezaei N, Seppänen MRJ, Mansouri D, Mahdaviani SA, Velayati AA. Movahedi M, et al. Among authors: eslaminejad a. Allergol Immunopathol (Madr). 2022 Jan 1;50(1):80-84. doi: 10.15586/aei.v50i1.388. eCollection 2022. Allergol Immunopathol (Madr). 2022. PMID: 34935317
Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
Baghaei P, Dastan F, Marjani M, Moniri A, Abtahian Z, Ghadimi S, Valizadeh M, Heshmatnia J, Sadat Mirenayat M, Abedini A, Kiani A, Eslaminejad A, MohammadReza Hashemian S, Jamaati H, Zali A, Akbar Velayati A, Tabarsi P. Baghaei P, et al. Among authors: eslaminejad a. Int Immunopharmacol. 2021 Mar;92:107329. doi: 10.1016/j.intimp.2020.107329. Epub 2020 Dec 26. Int Immunopharmacol. 2021. PMID: 33412395 Free PMC article.
An Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation from Drimia maritima (L.) Stearn): A Pilot Randomized Triple-Blinded Placebo-Controlled Clinical Trial.
Mohammadi-Araghi M, Eslaminejad A, Karegar-Borzi H, Mazloomzadeh S, Nejatbakhsh F. Mohammadi-Araghi M, et al. Among authors: eslaminejad a. Evid Based Complement Alternat Med. 2022 May 30;2022:5024792. doi: 10.1155/2022/5024792. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35677368 Free PMC article.
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F, Saffaei A, Haseli S, Marjani M, Moniri A, Abtahian Z, Abedini A, Kiani A, Seifi S, Jammati H, Hashemian SMR, Pourabdollah Toutkaboni M, Eslaminejad A, Heshmatnia J, Sadeghi M, Nadji SA, Dastan A, Baghaei P, Varahram M, Yousefian S, Salamzadeh J, Tabarsi P. Dastan F, et al. Among authors: eslaminejad a. Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4. Int Immunopharmacol. 2020. PMID: 32889241 Free PMC article. Clinical Trial.
National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19.
Mirenayat MS, Abedini A, Kiani A, Eslaminejad A, Adimi Naghan P, Malekmohammad M, Heshmatnia J, Nadji SA, Idani E, Zahiri R, Lookzadeh S, Sheikhzade H, Dastan F, Porabdollah Toutkaboni M, Rezaei MS, Askari E, Tabarsi P, Marjani M, Moniri A, Hashemian SMR, Farzanegan B, Abtahian Z, Yassari F, Mansouri N, Mansouri D, Vasheghani M, Mansourafshar B, Mokhber Dezfoli M, Soleimani S, Seifi S, Naghashzadeh F, Fakharian A, Varahram M, Jamaati H, Zali A, Velayati AA. Mirenayat MS, et al. Among authors: eslaminejad a. Iran J Pharm Res. 2022 Mar 30;21(1):e123947. doi: 10.5812/ijpr.123947. eCollection 2022 Dec. Iran J Pharm Res. 2022. PMID: 35765502 Free PMC article.
Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center.
Mahdaviani SA, Darougar S, Mansouri D, Tashayoie-Nejad S, Movahedi M, Aghdam KR, Ghaffaripour H, Baghaie N, Hassanzad M, Eslaminejad A, Fakharian A, Pourdowlat G, Heshmatnia J, Bakhshayeshkaram M, Boloursaz M, Tabarsi P, Hashemitari SK, Velayati AA. Mahdaviani SA, et al. Among authors: eslaminejad a. Interv Med Appl Sci. 2019 Mar;11(1):1-7. doi: 10.1556/1646.10.2018.49. Interv Med Appl Sci. 2019. PMID: 32148897 Free PMC article.
32 results